Pro-inflammatory cytokines in patients with low back pain: A comparative study

Slouma, Maroua; Kharrat, Lobna; Tezegdenti, Aymen; Metoui, Leila; Ghazouani, Ezzeddine; Dhahri, Rim; Gharsallah, Imen; Louzir, Bassem

doi:10.1016/j.reuma.2022.07.002

Información del artículo

Resumen

Texto completo

Bibliografía

Descargar PDF

Estadísticas

Figuras (1)

Tablas (3)

Table 1. Clinical characteristics of patients.

Table 2. Comparison of the pro-inflammatory cytokines between the two groups.

Table 3. Correlations between clinical parameter and cytokines.

Mostrar másMostrar menos

Abstract

Introduction and objectives

There are controversial results regarding the value of serum IL-8 and TNFα in patients with non-specific low back pain.

This study aimed to compare pro-inflammatory cytokines between patients with non-specific back pain and pain-free controls.

Materials and methods

We conducted a case–control study including 106 participants: 46 patients with chronic non-specific low back pain (G1) and 60 pain-free controls (G0). The interleukin (IL-)6, IL-8, IL-17, IL-23, IL-22, and Tumor necrosis factor α (TNFα) were measured. We collected demographic and clinical data, including age, gender, low back pain duration and radicular pain. The pain degree was assessed using the Visual Analogic Scale.

Results

The mean age was 43.17±8.7 years in G1. Radicular pain was found in 37 cases with a Visual Analogic Scale of 3.03±2.5mm. The magnetic resonance imaging was performed in (G1), showing disk herniation and degenerative disk disease in 54.3% (n=25) and 45.7% of cases (n=21), respectively. The IL-8 was higher in G1 (18.84±44.64 versus 4.34±1.23pg/mL, p:0.033). IL-8 levels correlated with TNFα (0.942, p<10–3), IL-6 (0.490, p=0.011) and Visual Analogic ScaleRadicular-pain (r:0.297, p:0.047).

IL-17 was higher in patients with restricted lumbar spine mobility (9.64±20.77 versus 1.19±2.54pg/mL, p:0.014).

Conclusions

Our results provide evidence that IL-8 and TNFα play a role in low back pain and radicular pain due to disk degeneration or herniation. These findings could potentially be used by future studies to develop new non-specific low back pain therapeutic strategies.

Keywords:

Back pain

Disk herniation

Cytokine

Interleukin-8

Tumor necrosis factor α

Interleukin-17

Resumen

Introducción y objetivos

Existen resultados controvertidos en cuanto al valor de la interleucina (IL) 8 y el factor de necrosis tumoral α (TNFα) séricos en pacientes con lumbalgia inespecífica.

Este estudio tuvo como objetivo comparar las citoquinas proinflamatorias entre pacientes con dolor de espalda inespecífico y controles sin dolor.

Materiales y métodos

Realizamos un estudio de casos y controles que incluyó a 106 participantes: 46 pacientes con dolor lumbar crónico inespecífico (G1) y 60 controles sin dolor (G0). Se midieron las IL-6, IL-8, IL-17, IL-23, IL-22 y el TNFα. Recopilamos datos demográficos y clínicos, incluidos la edad, el sexo, la duración del dolor lumbar y el dolor radicular. El grado de dolor se evaluó mediante la escala analógica visual.

Resultados

La edad media fue de 43,17±8,7 años en G1. Se encontró dolor radicular en 37 casos con una escala analógica visual de 3,03±2,5mm. La resonancia magnética se realizó en G1, mostrando hernia discal y enfermedad discal degenerativa en el 54,3% (n=25) y el 45,7% de los casos (n=21), respectivamente. La IL-8 fue mayor en G1 (18,84±44,64 versus 4,34±1,23pg/ml, p=0,033). Los niveles de IL-8 se correlacionaron con TNFα (0,942, p<10−3), IL-6 (0,490, p=0,011) y escala visual analógicadolor radicular (r=0,297, p=0,047).

IL-17 fue mayor en pacientes con movilidad restringida de la columna lumbar (9,64±20,77 versus 1,19±2,54pg/ml, p=0,014).

Conclusiones

Nuestros resultados proporcionan evidencia de que la IL-8 y el TNFα juegan un papel en el dolor lumbar y en el dolor radicular debido a la degeneración o a hernia discal. Estos hallazgos podrían potencialmente ser utilizados por estudios futuros para desarrollar nuevas estrategias terapéuticas no específicas para el dolor lumbar.

Palabras clave:

Dolor de espalda

Hernia discal

Citoquina

Interleucina 8

Factor de necrosis tumoral α

Interleucina 17

Texto completo

Introduction

Low back pain (LBP) is a global healthcare concern. Non-specific LBP is the most common form.1 It can be due to several diseases, such as disk disease (intervertebral disk degeneration (IDD) or lumbar disk herniation (LDH)), facet joint osteoarthritis, and spinal stenosis.2

Non-specific LBP is a very common disease that affects 70 to 90% of general population.3 Fifteen per cent of work absenteeism is caused by LBP.3 It can be responsible for disability and restricted lumbar range of motion.4

Thus, a better understanding of the pathophysiology of low back pain is necessary to ensure appropriate care for this potentially disabling disease.

Despite its frequency, LBP's diagnosis remains sometimes difficult and mainly based on the elimination of other spinal diseases.5 LBP pathophysiology is, up to now, unclear.

There are controversial results regarding the role of pro-inflammatory cytokines such as interleukin (IL-)6, IL-8, IL-17, IL-23, IL-22, and Tumor necrosis factor (TNFα) in the physiopathology of non-specific LBP5,6 and its recurrence.7

Besides, several studies showed that pro-inflammatory cytokines contribute to the pathogenesis of IDD and associated pain mechanisms.8,9

This study aimed to compare the value of these pro-inflammatory cytokines between patients with non-specific LBP and pain-free controls.

Material and methodsPatients

We conducted a case–control study from September 2019 to December 2020 including 106 participants:

-
G1: 46 consecutive patients with non-specific LBP recruited from the outpatient clinic of the rheumatology department.
-
G0: 60 pain-free controls recruited from different departments in the Military hospital of Tunis.

Inclusion criteria

Were included in this study patients with chronic non-specific LBP lasting>3 months.

Only patients with magnetic resonance imaging (MRI) showing single LDH or IDD were included in the study. The interpretation of MRIs was performed by a trained radiologist.

Exclusion criteria

Non-inclusions criteria for the two groups were: history of neoplasia, asthma, infections, chronic inflammatory bowel disease, psoriasis, auto-immune disease (rheumatoid arthritis, systemic lupus erythematosus), or steroids treatment.

Patients with LBP treated with surgery were not included.

Were excluded patients with LBP due to spondyloarthritis, infectious spondylodiscitis, or metastasis.

Clinical assessment

We collected demographic and clinical data, including age, gender, age at disease onset, LBP duration, radicular pain, and therapeutic management.

The pain degree was assessed using the Visual Analogic Scale (VAS). The VAS varied from “no pain” to “worst imaginable pain” (0–100mm).

Lumbar spine mobility was evaluated using Schober's test.10 A restricted lumbar motion was defined as a difference between the measurements in erect and flexion positions lower than 5cm.

Cytokine's measurement

The IL-6, IL-8, IL-17, IL-23, IL-22, and (TNFα) were measured. The blood samples were collected, centrifuged, and frozen at −80°C. IL-6, IL-8, and TNFα were measured using the chemiluminescence method, whereas IL-17, IL-22, and IL-23 levels were measured using the ELISA (Enzyme-linked Immunosorbent Assay).

Statistical analysis

Statistical analysis was performed using the Statistical Package for Social Sciences (SPSS) software version 25. We used descriptive statistics to identify the characteristics of the study population. Results were expressed as the mean±standard deviation (SD).

Continuous variables were compared using t-tests for normally distributed variables and the Mann–Whitney U test for non-normally distributed groups. Correlations were tested using the Pearson or Spearman correlation test, depending on data distribution. p-Value<0.05 was considered statistically significant.

To assess the normality of data, we used the Kolmogorov–Smirnov test. Receiver operating characteristic (ROC) curves were used for each cytokine to evaluate their ability to discriminate patients with non-specific LBP from pain-free controls.

Ethical consideration

This study was approved by eight members of the ethics committee of the hospital in May 2019.

All participants were requested to read and sign an informed consent form explaining the aim and process of the study.

ResultClinical and epidemiological characteristics of patients

All patients were Caucasian. There were 36 men in G1 and 46 in G0. The mean age was 43.17±8.7 years in G1 and 39.56±9.95 years in G0. The mean body mass index (BMI) was 27.31±3.47kg/m2.

Clinical characteristics of patients with non-specific LBP are summarized in Table 1.

Table 1.

Clinical characteristics of patients.

Age, mean±SD years	43.17±8.7
Age at the onset of LBP, mean±SD years	38.43±9.57
Body mass index, mean±SD kg/m2	27.31±3.47
Smoking (n (%))	13 (28%)

Comorbidities
Diabetes (n (%))	3 (6%)
Hypertension (n (%))	2 (4%)
Dyslipidemia (n (%))	5 (11%)

Clinical assessment
Radicular pain (n (%))	37 (80.4%)
VASbackpain, mean±SD	3.79±1.95
VASradicularpain, mean±SD	3.03±2.5

MRI features
Disk herniation (n (%))	25 (54.3%)
Degenerative disk disease (n (%))	21 (45.7%)

LBP: low back pain, VAS: Visual Analog Scale, MRI: magnetic resonance imaging.

The mean age at the onset of LBP was 38.43±9.75 years.

The mean duration of LBP was 4.72±3.03 years.

Radicular pain was found in 37 cases with a VAS of 3.03±2.5mm. The magnetic resonance imaging was performed for all patients (G1), showing LDH and IDD in 54.3% (n=25) and 45.7% of cases (n=21), respectively.

Spine limitation was found in 15 cases.

Comparison of cytokines

The IL-8 was higher in G1 (18.84±44.64 versus 4.34±1.23pg/mL, p:0.033). There was no significant difference between the two groups regarding the other cytokines. There were no differences between patients with LDH or IDD regarding IL-8 (23.91±62.64 versus 14.95±20.64pg/mL, p:0.29) and TNFα (19.8±46.7 versus 7.2±1.3pg/mL, p:0.75).

IL-17 was higher in patients with restricted lumbar spine mobility (Table 2).

Table 2.

Comparison of the pro-inflammatory cytokines between the two groups.

	Pain-free controls	Patients	p	Lumbar spine mobility		p
				Normal	Restricted
IL-6	2.17±1.05	1.09±1.28	0.39	1.83±1.01	2.5±1.61	0.26
TNFα	7.25±2.44	13.11±31.92	0.324	15.45±38.18	7.64±1.33	0.53
IL-8	4.34±1.23	18.84±44.64	0.033	21.27±53.33	13.84±16.5	0.62
IL-17	1.10±1.53	3.73±11.79	0.235	1.19±2.54	9.64±20.77	0.014
IL-22	13.10±15.27	14.42±8.17	0.725	15.42±9.45	12.34±4.05	0.21
IL-23	2.31±6.32	0.81±1.80	0.151	0.54±1.25	1.42±2.65	0.53

Values were expressed as mean±SD, p: probability value, IL: interleukin, TNFα: Tumor Necrosis Factor α.

Correlations between clinical parameters and cytokines

As shown in Table 3, a correlation was found between: IL-8 and TNFα (r:0.942, p<10−3), IL-8 and IL-6 (r:0.490, p: 0.011), and IL-17 and IL-6 (r:0.945, p<10−3). IL-8 levels correlated also with VASRadicular-pain (r:0.297, p:0.047).

Table 3.

Correlations between clinical parameter and cytokines.

	VASbackpain	VASradicularpain	TNFα	IL-8	IL-17	IL-22	IL-23	IL-6
VASbackpain	–	0.440**	0.035	0.152	−0.144	0.021	−0.063	0.060
VASradicular pain	0.440**	–	0.192	0.297*	−0.040	−0.050	−0.166	−0.096
BMI	0.149	0.2	0.311	0.201	0.386	−0.174	−0.048	0.255
TNFα	0.035	0.192	–	0.942***	−0.048	−0.113	−0.087	0.117
IL-6	0.060	−0.096	0.117	0.490*	0.945**	−0.328	−0.332	–
IL-8	0.152	0.297*	0.942**	–	−0.036	−0.111	−0.137	0.490*
IL-17	−0.144	−0.040	−0.048	−0.036	–	−0.043	−0.085	0.945**
IL-22	0.021	−0.050	−0.113	−0.111	−0.043	–	0.123	−0.328
IL-23	−0.063	−0.166	−0.087	−0.137	−0.085	0.123	–	−0.332

Data are presented as the r value in Pearson's correlation test.

*

p<0.05.

**

p<0.01.

***

p<0.001.

p: probability value, IL: interleukin, TNFα: Tumor Necrosis Factor α, VAS: Visual Analog Scale, BMI: body mass index.

Discriminative value of pro-inflammatory cytokines between patients with LBP and pain-free controls

The IL-8 could differentiate patients in G1 from G0 with a cutoff of 4.5pg/mL. The area under the curve was good (0.917) (Fig. 1). The sensitivity and specificity were 91.3% and 90%, respectively.

Fig. 1.

Receiver operating characteristic curve (ROC) showing the discriminative value of IL-8 between LBP and pain-free controls.

(0.06MB).

Discussion

We attempted to study pro-inflammatory cytokines, including IL-6, IL-8, IL-17, IL-23, IL-22, and TNFα, in patients with chronic LBP. We found that IL-8 was higher in patients with non-specific LBP, and it was able to differentiate patients with LBP from pain-free controls with a cutoff of 4.5pg/mL.

Several studies have analyzed the role of cytokines in LBP, with variable results but with a predominance of pro-inflammatory cytokines, indicating the role of inflammatory process in causing disk damage.

In a study including 127 patients with lumbar radicular pain due to LDH, the authors demonstrated that chronic pain patients had increased serum levels of IL-8 at 6 weeks and 12 months after LDH.11 These findings suggest that IL-8 may contribute to the development of chronic pain after LDH.11 Moreover, it has been proven in animal models that IL-8 was implicated in the pathophysiology of neuropathic pain.12

Likewise, Wang et al. demonstrated that IL-8 and TNFα levels were higher in patients with LBP and sciatica than healthy controls. They also found that TNFα correlated with Oswestry Disability Index (r:0.629, p:0.001)13 which is a patient reported outcomes questionnaire used to assess functional disability in back pain patients.14

This finding suggests that pro-inflammatory cytokines contribute to the generation and persistence of pain.

In a study including 155 women with acute LBP, an association was found between TNFα elevation and pain severity. TNFα was also associated with disability.15

In a longitudinal study including 120 patients with LBP matched to a healthy control group, the TNFα was positive in 57.6% LBP patients versus 12.3% of controls at the beginning of the study. The TNFα levels decreased after 10 days of multidisciplinary therapy, then remained constantly high in LBP patients. Nevertheless, no significant correlation was found between TNFα levels and pain.16

Krock et al. found that IL-8 levels in the spinal fluid were higher in patients with chronic LBP due to IDD than those with IDD without pain. The authors highlighted the effect of blocking IL-8 receptor signaling on reducing LBP behaviors and disk inflammation in a mouse model.17

Karppinen et al. assessed the serum biomarkers in chronic LBP patients with lumbar Modic change. They found that IL-8 and TNFα were lower among these patients than pain-free controls.18

Schroeder et al. showed that TNFα was higher in patients with intervertebral discs with type II Modic changes.19

These findings suggest the possible pathophysiological role of IL-8 and TNFα in LBP and radicular pain due to IDD or LDH. However, their role in LBP related to vertebral bone marrow lesions such as Modic change remains unclear and needs to be more closely assessed.19

In our study, a strong correlation was found between IL-8 and TNFα. This correlation (IL-8/TNFα r:0.35; p=0.003) was also noted in the study of Licciardone et al., highlighting the link between pro-inflammatory cytokines in non-specific LBP.20

Zhang Y et al. demonstrated that intervertebral disk cells could produce IL-1, IL-7, and IL-8.21 They suggested that these cytokines mediate discogenic pain by stimulating nerve endings in intervertebral disk and contribute to the persistence of this pain by diffusing these cytokines to nearby tissues.21

IL-8 can also promote angiogenesis and attract neutrophils in pathological sites.22

Besides, IL-8 can promote microglial activation in the lumbar disk herniation rate model.23 Chronic pain maintenance can be explained by delayed IL-8 upregulation in the spinal cord and the dorsal root ganglion.23

These findings suggest that IL-8 inhibition may be a potential therapy for chronic low back pain.

Several studies emphasize the role of IL-17 in the pathophysiology of IDD and demonstrate that IL-17 is an important regulator of inflammation in disk diseases.24,25

Besides, IL-17 may contribute to the pain genesis in patients with LBP. Cheng et al. found that VAS pain score was positively correlated with IL-17 concentration (r=0.458, p=0.007) in patients with LBP. IL-17 levels were also higher in patients with ruptured lumbar disk (12.13±3.62pg/ml) than those with non-ruptured lumbar discs (5.06±3.78pg/ml, p=0.003) and healthy controls (1.31±0.77pg/ml, p<0.001).8

In our study, IL-17 was significantly higher in patients with spine limitations.

A correlation was found between IL-6 and both IL-8 and IL-17. In a study assessing IL-6 expression in paravertebral muscle, annulus fibrosus, and nucleus pulposus biopsies, the IL-6 was found in all lumbar disk hernias biopsies but not in controls. This result suggests that the lumbar disk hernia is associated with a local inflammatory process. Nevertheless, there was no correlation between IL-6 expression and VAS scores.26

Notably, some authors highlighted that elevated pro-inflammatory cytokines levels in LBP were due to adipocytes stimulation in overweight and obese patients.27 In our study there was no correlation between cytokines levels and BMI. Pro-inflammatory cytokines like IL-6, IL-8 and TNFα correlated to BMI in subjects without LBP.28–30 To our knowledge, the correlation between pro-inflammatory cytokines was not assessed in LBP patients.

To our knowledge, this study is the first to determine an IL-8 threshold to distinguish LBP patients from healthy controls. The results of our study are encouraging. However, some limitations must be considered, notably the small number of patients with LBP.

Conclusion

IL-8 seemed to be the most important pro-inflammatory cytokine in patients with disk-disease, as it was significantly higher in patients with LBP.

IL-8 correlated with VAS, highlighting the role of this cytokine in the development of chronic pain in patients with disk disease.

TNFα concentrations correlated with IL-8 and IL-17 levels were higher in patients with restricted lumbar pain, suggesting that these cytokines might play a role in the pathophysiology of disk disease. These findings could potentially be used by future studies to develop new LBP therapeutic strategies.

Authors’ contributions

-
Dr. Maroua SLOUMA: Methodology and Writing – review & editing
-
Dr. Lobna KHARRAT: Roles/Writing – original draft
-
Dr. Aymen TEZEGDENTI: data curation and funding acquisition
-
Dr. Rim DHAHRI: formal analysis
-
Dr Ezzeddine GHAZOUANI: project administration
-
Dr. Leila METOUI: conceptualisation
-
Dr. Imen GHARSALLAH: visualization
-
Dr. Bassem LOUZIR: visualization and validation

Availability of data and material

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Code availability (software application or custom code)

Not applicable.

Ethics approval

This study was approved by the ethics committee of the Hospital.

Consent to participate

A consent has been signed by each patient.

Funding

The authors declare that they have no funding for the research.

Conflict of interest

None.

Acknowledgements

None.

References

[1]

C. Maher, M. Underwood, R. Buchbinder.

Non-specific low back pain.

Lancet Lond Engl, 389 (2017), pp. 736-747

[2]

A.R. Last, K. Hulbert.

Chronic low back pain: evaluation and management.

Am Fam Physician, 79 (2009), pp. 1067-1074

Medline

[3]

Y.Z. Lim, Y. Wang, F.M. Cicuttini, H.J. Hughes, L. Chou, D.M. Urquhart, et al.

Association between inflammatory biomarkers and nonspecific low back pain: a systematic review.

Clin J Pain, 36 (2020), pp. 379-389

http://dx.doi.org/10.1097/AJP.0000000000000810 | Medline

[4]

R.A. Laird, J. Gilbert, P. Kent, J.L. Keating.

Comparing lumbo-pelvic kinematics in people with and without back pain: a systematic review and meta-analysis.

BMC Musculoskelet Disord, 15 (2014), pp. 229

http://dx.doi.org/10.1186/1471-2474-15-229 | Medline

[5]

J.A. Teodorczyk-Injeyan, J.J. Triano, H.S. Injeyan.

Nonspecific low back pain: inflammatory profiles of patients with acute and chronic pain.

Clin J Pain, 35 (2019), pp. 818-825

http://dx.doi.org/10.1097/AJP.0000000000000745 | Medline

[6]

R. van den Berg, E.M. Jongbloed, E.I.T. de Schepper, S.M.A. Bierma-Zeinstra, B.W. Koes, P.a.J. Luijsterburg.

The association between pro-inflammatory biomarkers and nonspecific low back pain: a systematic review.

Spine J Off J North Am Spine Soc, 18 (2018), pp. 2140-2151

[7]

D.M. Klyne, M.F. Barbe, P.W. Hodges.

Relationship between systemic inflammation and recovery over 12 months after an acute episode of low back pain.

Spine J Off J North Am Spine Soc, 22 (2022), pp. 214-225

[8]

L. Cheng, W. Fan, B. Liu, X. Wang, L. Nie.

Th17 lymphocyte levels are higher in patients with ruptured than non-ruptured lumbar discs, and are correlated with pain intensity.

Injury, 44 (2013), pp. 1805-1810

http://dx.doi.org/10.1016/j.injury.2013.04.010 | Medline

[9]

A.N. Khan, H.E. Jacobsen, J. Khan, C.G. Filippi, M. Levine, R.A. Lehman, et al.

Inflammatory biomarkers of low back pain and disc degeneration: a review.

Ann N Y Acad Sci, 1410 (2017), pp. 68-84

http://dx.doi.org/10.1111/nyas.13551 | Medline

[10]

M. Cidem, I. Karacan, M. Uludag.

Normal range of spinal mobility for healthy young adult Turkish men.

Rheumatol Int, 32 (2012), pp. 2265-2269

http://dx.doi.org/10.1007/s00296-011-1953-4 | Medline

[11]

L.M. Pedersen, E. Schistad, L.M. Jacobsen, C. Røe, J. Gjerstad.

Serum levels of the pro-inflammatory interleukins 6 (IL-6) and -8 (IL-8) in patients with lumbar radicular pain due to disc herniation: a 12-month prospective study.

Brain Behav Immun, 46 (2015), pp. 132-136

http://dx.doi.org/10.1016/j.bbi.2015.01.008 | Medline

[12]

J. Khan, H. Hassun, T. Zusman, O. Korczeniewska, E. Eliav.

Interleukin-8 levels in rat models of nerve damage and neuropathic pain.

Neurosci Lett, 657 (2017), pp. 106-112

http://dx.doi.org/10.1016/j.neulet.2017.07.049 | Medline

[13]

K. Wang, J.P. Bao, S. Yang, X. Hong, L. Liu, X.H. Xie, et al.

A cohort study comparing the serum levels of pro- or anti-inflammatory cytokines in patients with lumbar radicular pain and healthy subjects.

Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res Soc, 25 (2016), pp. 1428-1434

[14]

J.C. Fairbank, P.B. Pynsent.

The Oswestry disability index.

Spine, 25 (2000), pp. 2940-2952

http://dx.doi.org/10.1097/00007632-200011150-00017 | Medline

[15]

C. Romero-Sanchez, D.A. Jaimes, J. Londoño, J. De Avila, J.E. Castellanos, J.M. Bello, et al.

Association between Th-17 cytokine profile and clinical features in patients with spondyloarthritis.

Clin Exp Rheumatol, 29 (2011), pp. 828-834

Medline

[16]

H. Wang, M. Schiltenwolf, M. Buchner.

The role of TNF-alpha in patients with chronic low back pain-a prospective comparative longitudinal study.

Clin J Pain, 24 (2008), pp. 273-278

http://dx.doi.org/10.1097/AJP.0b013e31816111d3 | Medline

[17]

E. Krock, M. Millecamps, K.M. Anderson, A. Srivastava, T.E. Reihsen, P. Hari, et al.

Interleukin-8 as a therapeutic target for chronic low back pain: upregulation in human cerebrospinal fluid and pre-clinical validation with chronic reparixin in the SPARC-null mouse model.

EBioMedicine, 43 (2019), pp. 487-500

http://dx.doi.org/10.1016/j.ebiom.2019.04.032 | Medline

[18]

J. Karppinen, K. Koivisto, J. Ketola, M. Haapea, M. Paananen, K.H. Herzig, et al.

Serum biomarkers for Modic changes in patients with chronic low back pain.

Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res Soc, 30 (2021), pp. 1018-1027

[19]

G.D. Schroeder, D.Z. Markova, J.D. Koerner, J.A. Rihn, A.S. Hilibrand, A.R. Vaccaro, et al.

Are Modic changes associated with intervertebral disc cytokine profiles?.

Spine J Off J North Am Spine Soc, 17 (2017), pp. 129-134

[20]

J.C. Licciardone, C.M. Kearns, L.M. Hodge, M.V.W. Bergamini.

Associations of cytokine concentrations with key osteopathic lesions and clinical outcomes in patients with nonspecific chronic low back pain: results from the OSTEOPATHIC Trial.

J Am Osteopath Assoc, 112 (2012), pp. 596-605

http://dx.doi.org/10.7556/jaoa.2012.112.9.596 | Medline

[21]

Y. Zhang, A. Chee, P. Shi, S.L. Adams, D.Z. Markova, D.G. Anderson, et al.

Intervertebral disc cells produce interleukins found in patients with back pain.

Am J Phys Med Rehabil, 95 (2016), pp. 407-415

http://dx.doi.org/10.1097/PHM.0000000000000399 | Medline

[22]

A. Li, S. Dubey, M.L. Varney, B.J. Dave, R.K. Singh.

IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis.

J Immunol Baltim Md, 170 (1950 2003), pp. 3369-3376

[23]

S.J. Kim, S.M. Park, Y.W. Cho, Y.J. Jung, D.G. Lee, S.H. Jang, et al.

Changes in expression of mRNA for interleukin-8 and effects of interleukin-8 receptor inhibitor in the spinal dorsal horn in a rat model of lumbar disc herniation.

Spine, 36 (2011), pp. 2139-2146

http://dx.doi.org/10.1097/BRS.0b013e31821945a3 | Medline

[24]

M.F. Shamji, L.A. Setton, W. Jarvis, S. So, J. Chen, L. Jing, et al.

Proinflammatory cytokine expression profile in degenerated and herniated human intervertebral disc tissues.

Arthritis Rheum, 62 (2010), pp. 1974-1982

http://dx.doi.org/10.1002/art.27444 | Medline

[25]

M.A. Gabr, L. Jing, A.R. Helbling, S.M. Sinclair, K.D. Allen, M.F. Shamji, et al.

Interleukin-17 synergizes with IFNγ or TNFα to promote inflammatory mediator release and intercellular adhesion molecule-1 (ICAM-1) expression in human intervertebral disc cells.

J Orthop Res Off Publ Orthop Res Soc, 29 (2011), pp. 1-7

[26]

P. Andrade, G. Hoogland, M.A. Garcia, H.W. Steinbusch, M.A. Daemen, V. Visser-Vandewalle.

Elevated IL-1β and IL-6 levels in lumbar herniated discs in patients with sciatic pain.

Eur Spine J Off Publ Eur Spine Soc Eur Spinal Deform Soc Eur Sect Cerv Spine Res Soc, 22 (2013), pp. 714-720

[27]

I.M. da Cruz Fernandes, R.Z. Pinto, P. Ferreira, F.S. Lira.

Low back pain, obesity, and inflammatory markers: exercise as potential treatment.

J Exerc Rehabil, 14 (2018), pp. 168-174

http://dx.doi.org/10.12965/jer.1836070.035 | Medline

[28]

K. Popko, E. Gorska, A. Stelmaszczyk-Emmel, R. Plywaczewski, A. Stoklosa, D. Gorecka, et al.

Proinflammatory cytokines IL-6 and TNF-α and the development of inflammation in obese subjects.

Eur J Med Res, 15 (2010), pp. 120-122

http://dx.doi.org/10.1186/2047-783x-15-s2-120 | Medline

[29]

M. Gholami, F. Sharifi, S. Shahriari, K. Khoshnevisan, B. Larijani, M.M. Amoli.

Association of interleukin-6 polymorphisms with obesity: a systematic review and meta-analysis.

Cytokine, 123 (2019), pp. 154769

http://dx.doi.org/10.1016/j.cyto.2019.154769 | Medline

[30]

L. Utsal, V. Tillmann, M. Zilmer, J. Mäestu, P. Purge, J. Jürimäe, et al.

Elevated serum IL-6, IL-8, MCP-1 CRP, and IFN-γ levels in 10–11-year-old boys with increased BMI.

Horm Res Paediatr, 78 (2012), pp. 31-39

http://dx.doi.org/10.1159/000339831 | Medline

Indexada en:

Síguenos:

Suscribirse:

Indexada en:

Síguenos:

Suscribirse:

Suscríbase a la newsletter